• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

多组分植物疗法日益兴起:“一种药物适合所有人”的模式是否正在瓦解?

Multicomponent phytotherapeutic approach gaining momentum: Is the "one drug to fit all" model breaking down?

机构信息

Medicinal Chemistry Division, Indian Institute of Integrative Medicine, Sanat Nagar, Srinagar, India.

出版信息

Phytomedicine. 2013 Dec 15;21(1):1-14. doi: 10.1016/j.phymed.2013.07.015. Epub 2013 Sep 12.

DOI:10.1016/j.phymed.2013.07.015
PMID:24035674
Abstract

Natural product based drugs constitute a substantial proportion of the pharmaceutical market particularly in the therapeutic areas of infectious diseases and oncology. The primary focus of any drug development program so far has been to design selective ligands (drugs) that act on single selective disease targets to obtain highly efficacious and safe drugs with minimal side effects. Although this approach has been successful for many diseases, yet there is a significant decline in the number of new drug candidates being introduced into clinical practice over the past few decades. This serious innovation deficit that the pharmaceutical industries are facing is due primarily to the post-marketing failures of blockbuster drugs. Many analysts believe that the current capital-intensive model-"the one drug to fit all" approach will be unsustainable in future and that a new "less investment, more drugs" model is necessary for further scientific growth. It is now well established that many diseases are multi-factorial in nature and that cellular pathways operate more like webs than highways. There are often multiple ways or alternate routes that may be switched on in response to the inhibition of a specific target. This gives rise to the resistant cells or resistant organisms under the specific pressure of a targeted agent, resulting in drug resistance and clinical failure of the drug. Drugs designed to act against individual molecular targets cannot usually combat multifactorial diseases like cancer, or diseases that affect multiple tissues or cell types such as diabetes and immunoinflammatory diseases. Combination drugs that affect multiple targets simultaneously are better at controlling complex disease systems and are less prone to drug resistance. This multicomponent therapy forms the basis of phytotherapy or phytomedicine where the holistic therapeutic effect arises as a result of complex positive (synergistic) or negative (antagonistic) interactions between different components of a cocktail. In this approach, multicomponent therapy is considered to be advantageous for multifactorial diseases, instead of a "magic bullet" the metaphor of a "herbal shotgun" might better explain the state of affairs. The different interactions between various components might involve the protection of an active substance from decomposition by enzymes, modification of transport across membranes of cells or organelles, evasion of multidrug resistance mechanisms among others.

摘要

天然产物药物构成了药物市场的重要组成部分,尤其是在传染病和肿瘤学等治疗领域。迄今为止,任何药物开发计划的主要重点都是设计选择性配体(药物),这些配体作用于单一的选择性疾病靶点,以获得高效、安全且副作用最小的药物。尽管这种方法在许多疾病中都取得了成功,但在过去几十年中,进入临床实践的新药候选物数量却显著下降。制药行业面临的这种严重创新不足主要是由于重磅炸弹药物的上市后失败。许多分析人士认为,当前资本密集型模式——“一种药物适合所有人”的方法在未来将不可持续,需要一种新的“投资少、药物多”的模式来推动进一步的科学发展。现在已经确定,许多疾病本质上是多因素的,细胞途径更像是网络而不是高速公路。通常有多种方法或替代途径可以在特定靶点被抑制时被激活。这导致在特定靶向药物的特定压力下产生耐药细胞或耐药生物,从而导致药物耐药性和药物临床失败。针对单个分子靶点设计的药物通常无法治疗癌症等多因素疾病,也无法治疗影响多种组织或细胞类型的疾病,如糖尿病和免疫炎症性疾病。同时作用于多个靶点的联合药物更能控制复杂的疾病系统,且不易产生耐药性。这种多组分治疗构成了植物疗法或植物药的基础,整体治疗效果是由于鸡尾酒中不同成分之间复杂的积极(协同)或消极(拮抗)相互作用产生的。在这种方法中,多组分治疗被认为对多因素疾病是有利的,而不是“万能药”,“草药霰弹枪”的比喻可能更能解释这种情况。不同成分之间的不同相互作用可能涉及保护活性物质免受酶的分解、改变细胞或细胞器的跨膜运输、逃避多药耐药机制等。

相似文献

1
Multicomponent phytotherapeutic approach gaining momentum: Is the "one drug to fit all" model breaking down?多组分植物疗法日益兴起:“一种药物适合所有人”的模式是否正在瓦解?
Phytomedicine. 2013 Dec 15;21(1):1-14. doi: 10.1016/j.phymed.2013.07.015. Epub 2013 Sep 12.
2
[Development of antituberculous drugs: current status and future prospects].[抗结核药物的研发:现状与未来前景]
Kekkaku. 2006 Dec;81(12):753-74.
3
Multi-target therapeutics: when the whole is greater than the sum of the parts.多靶点疗法:整体大于部分之和。
Drug Discov Today. 2007 Jan;12(1-2):34-42. doi: 10.1016/j.drudis.2006.11.008. Epub 2006 Nov 28.
4
[Design of multiple targeted drugs].[多种靶向药物的设计]
Yao Xue Xue Bao. 2009 Mar;44(3):276-81.
5
Anticancer Drug Development: The Way Forward.抗癌药物研发:前进之路
Oncologist. 1996;1(3):180-181.
6
Complex interactions between phytochemicals. The multi-target therapeutic concept of phytotherapy.植物化学物质的复杂相互作用。植物疗法的多靶点治疗概念。
Curr Drug Targets. 2011 Jan;12(1):122-32. doi: 10.2174/138945011793591626.
7
Cancer Drug Development: New Targets for Cancer Treatment.癌症药物研发:癌症治疗的新靶点
Oncologist. 1996;1(3):II-III.
8
[Frontier of mycobacterium research--host vs. mycobacterium].[分枝杆菌研究前沿——宿主与分枝杆菌]
Kekkaku. 2005 Sep;80(9):613-29.
9
Synergy research: approaching a new generation of phytopharmaceuticals.协同作用研究:迈向新一代植物药
Phytomedicine. 2009 Mar;16(2-3):97-110. doi: 10.1016/j.phymed.2008.12.018.
10
Protein promiscuity: drug resistance and native functions--HIV-1 case.蛋白质的多特异性:耐药性与天然功能——以HIV-1为例
J Biomol Struct Dyn. 2005 Jun;22(6):615-24. doi: 10.1080/07391102.2005.10531228.

引用本文的文献

1
Biopesticidal Efficacy and Safety of Azadirachtin: Broad-Spectrum Effects on Ectoparasites Infesting Goldfish, (Linn. 1758).印楝素的生物杀虫效力与安全性:对侵染金鱼(1758年林奈命名)的体外寄生虫的广谱作用
ACS Omega. 2025 Mar 25;10(13):13269-13277. doi: 10.1021/acsomega.4c10920. eCollection 2025 Apr 8.
2
The Dawn till Dusk of phytopharmaceuticals.植物药的从早到晚
Saudi Pharm J. 2024 Nov;32(11):102185. doi: 10.1016/j.jsps.2024.102185. Epub 2024 Oct 2.
3
Understanding of black salve toxicity by multi-compound cytotoxicity assays.
多化合物细胞毒性测定法对黑药膏毒性的认识。
BMC Complement Med Ther. 2022 Sep 20;22(1):247. doi: 10.1186/s12906-022-03721-y.
4
Interactions between Medical Plant-Derived Bioactive Compounds: Focus on Antimicrobial Combination Effects.药用植物来源的生物活性化合物之间的相互作用:聚焦抗菌联合效应
Antibiotics (Basel). 2022 Jul 28;11(8):1014. doi: 10.3390/antibiotics11081014.
5
Berberine and Oligomeric Proanthocyanidins Exhibit Synergistic Efficacy Through Regulation of PI3K-Akt Signaling Pathway in Colorectal Cancer.小檗碱和原花青素低聚物通过调控PI3K-Akt信号通路对结直肠癌发挥协同疗效。
Front Oncol. 2022 May 4;12:855860. doi: 10.3389/fonc.2022.855860. eCollection 2022.
6
Recent advances in the development of active hybrid molecules in the treatment of cardiovascular diseases.用于治疗心血管疾病的活性杂合分子开发的最新进展。
Bioorg Med Chem. 2022 May 15;62:116706. doi: 10.1016/j.bmc.2022.116706. Epub 2022 Mar 11.
7
Traditional Tibetan Medicine Twenty-Five Wei'er Tea Pills Ameliorate Rheumatoid Arthritis Based on Chemical Crosstalk Between Gut Microbiota and the Host.传统藏药二十五味味儿茶丸基于肠道微生物群与宿主之间的化学串扰改善类风湿性关节炎。
Front Pharmacol. 2022 Feb 10;13:828920. doi: 10.3389/fphar.2022.828920. eCollection 2022.
8
Towards Advances in Medicinal Plant Antimicrobial Activity: A Review Study on Challenges and Future Perspectives.迈向药用植物抗菌活性研究进展:关于挑战与未来展望的综述研究
Microorganisms. 2021 Sep 27;9(10):2041. doi: 10.3390/microorganisms9102041.
9
Are Nutraceuticals Beneficial in Chronic Kidney Disease?营养保健品对慢性肾脏病有益吗?
Pharmaceutics. 2021 Feb 6;13(2):231. doi: 10.3390/pharmaceutics13020231.
10
Synergy and antagonism in natural product extracts: when 1 + 1 does not equal 2.天然产物提取物中的协同作用和拮抗作用:当 1 + 1 不等于 2 时。
Nat Prod Rep. 2019 Jun 19;36(6):869-888. doi: 10.1039/c9np00011a.